Jacquet-Francillon Nicolas, Cornillon Jerome, Flandrin Pascale, Rigollet Lauren, Prevot Nathalie, Tavernier Emmanuelle, Bonnefoy Pierre-Benoit
Department of Nuclear Medicine, University Hospital, Saint-Etienne, France.
Lucien-Neuwirth Institute of Cancerology, Clinical Hematology Department, Saint-Priest-en-Jarez, France.
Curr Res Transl Med. 2021 May;69(2):103272. doi: 10.1016/j.retram.2020.103272. Epub 2021 Jan 18.
Promyelocytic sarcoma is an uncommon solid tumor made up of myeloblasts. It is characterized, like acute promyelocytic leukemia (APL), by a chromosomal translocation t(15;17) involving the retinoic acid receptor alpha (RARalpha) and the promyelocytic gene (PML). The diagnosis and monitoring of promyelocytic sarcoma is a challenge due to the rarity and severity of the disease. We describe a case with several initial sites and without APL. The patient was monitored with regular 18F-FDG PET/CT from diagnosis to complete response. The evolution of PET/CT imageries was compared to the quantification of PML-RARα fusion gene by RQ-PCR. In promyelocytic sarcoma medical care, 18F-FDG PET/CT appears to be an attractive tool for finding targets for biopsy, for the primary staging, for assessing therapeutic response and for detecting early relapse.
早幼粒细胞肉瘤是一种由成髓细胞构成的罕见实体瘤。与急性早幼粒细胞白血病(APL)一样,它的特征是涉及维甲酸受体α(RARα)和早幼粒细胞基因(PML)的染色体易位t(15;17)。由于该疾病的罕见性和严重性,早幼粒细胞肉瘤的诊断和监测具有挑战性。我们描述了一例有多个初始病灶且无APL的病例。从诊断到完全缓解,对该患者定期进行18F-FDG PET/CT监测。将PET/CT图像的演变与通过RQ-PCR对PML-RARα融合基因的定量进行比较。在早幼粒细胞肉瘤的医疗中,18F-FDG PET/CT似乎是一种有吸引力的工具,可用于寻找活检靶点、进行初始分期、评估治疗反应以及检测早期复发。